Valuation: FunPep Company Limited

Market Cap 2.43B 15.45M 13.59M 12.85M 11.66M 21.89M 1.48B 22.02M 154M 59.42M 757M 58.01M 56.75M P/E 2024
-4.22x
P/E 2025 -1.63x
Enterprise Value 664M 4.22M 3.71M 3.51M 3.18M 5.98M 405M 6.01M 42.01M 16.22M 207M 15.84M 15.49M EV / Sales 2024
338x
EV / Sales 2025 -
Free-Float
79.91%
Yield 2024 *
-
Yield 2025 -
09/03 FunPep Company Limited announced that it has received ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
20/02 FunPep Company Limited announced that it expects to receive ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
10/03/25 FunPep Company Limited announced that it has received ¥3.6 million in funding from SBI Securities Co., Ltd. CI
21/02/25 FunPep Company Limited announced that it expects to receive ¥3.6 million in funding from SBI Securities Co., Ltd. CI
22/07/24 FunPep Company Limited announced that it has received ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
05/07/24 FunPep Company Limited announced that it expects to receive ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
21/03/24 FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
04/03/24 FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
14/11/23 FunPep Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
15/05/23 FunPep Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
01/10/22 FunPep Company Limited completed the acquisition of Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
14/07/22 FunPep Company Limited agreed to acquire Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
13/12/21 FunPep Company Limited announced that it has received ¥3.741 million in funding from SBI Securities Co., Ltd., Investment Arm CI
1 day-2.04%
1 week-4.00%
Current month-9.43%
1 month-4.00%
3 months-18.64%
6 months-42.86%
Current year-41.46%
1 week 47
Extreme 47
50
1 month 47
Extreme 47
54
Current year 45
Extreme 45
130
1 year 45
Extreme 45
130
3 years 45
Extreme 45
325
5 years 45
Extreme 45
477
10 years 45
Extreme 45
843
Manager TitleAgeSince
Director of Finance/CFO 53 01/05/2015
President 62 01/01/2020
Chief Tech/Sci/R&D Officer 55 01/07/2015
Director TitleAgeSince
Chairman 78 01/03/2015
Director/Board Member 62 01/03/2015
Director/Board Member 55 01/12/2015
Date Insider Type Main position Quantity % Market Cap. Importance
28/4/25
Sola KK
OthersCompany 30,000 0.0926%
28/4/25
Sola KK
OthersCompany 50,000 0.1543%
28/4/25 Others 40,000 0.1234%
Change 5-day change 1-year change 3-year change Capi.($)
-2.04%-4.00%-54.29%-71.08% 15.78M
+2.64%+7.07%+11.87%+38.40% 47.97B
+0.14%+0.24%+49.69%+36.83% 44.5B
-1.50%+4.75%+338.30%+615.03% 43.93B
+1.62%+0.14%+10.02%+98.83% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.01%-0.87%+23.56%+151.14% 17.27B
-0.49%+8.96%+8.21% - 15.34B
+1.76%+2.98%+29.13%+45.78% 15.3B
+2.03%-3.12% - - 14.82B
Average +0.42%+2.02%+46.85%+120.22% 27B
Weighted average by Cap. +0.65%+2.97%+75.18%+163.69%

Financials

2024 2025
Net sales 6M 38.12K 33.53K 31.7K 28.75K 54K 3.66M 54.32K 380K 147K 1.87M 143K 140K -
Net income -889M -5.65M -4.97M -4.7M -4.26M -8M -542M -8.05M -56.24M -21.72M -277M -21.2M -20.75M -1.91B -12.14M -10.68M -10.1M -9.16M -17.2M -1.17B -17.3M -121M -46.69M -595M -45.58M -44.59M
Net Debt -2.35B -14.9M -13.11M -12.4M -11.24M -21.11M -1.43B -21.24M -148M -57.32M -730M -55.96M -54.75M -1.77B -11.23M -9.88M -9.34M -8.47M -15.91M -1.08B -16M -112M -43.2M -550M -42.17M -41.26M
Logo FunPep Company Limited
FunPep Co Ltd is a Japan-based company engaged in the research and development business for pharmaceuticals. The main business is to promote research and development of functional peptides, which are the results of research at the Graduate School of Medicine, Osaka University, and to put them into practical use in the business fields such as pharmaceuticals, cosmetics and medical devices. The business model defines its technical area as a functional peptide-based area and a related area that has synergies with it. The Research & Development pipeline is composed of research themes for antibody-inducing peptides and developed products. The Company is engaged in the sale of peptide active ingredients through cosmetic raw material trading companies or sales companies.
Employees
-
Date Price Change Volume
28/09/26 JPY 48.00 -2.04% 277,700
25/09/26 JPY 49.00 0.00% 126,600
24/09/26 JPY 49.00 -2.00% 174,100

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4881 Stock